默克Zepatier定价

StephenW

Merck Zepatier Pricing

http://www.nasdaq.com/article/merck-revenue-and-profit-falls--update-20160203-00914

Merck set a list price for Zepatier of $54,600 a patient for a 12-week treatment, more than 30% below the listprices for competing drugs from Gilead and AbbVie Inc., though in line with net prices for those drugs after discounts,according to Merck.

Merck said it expects the price for Zepatier to maximize its revenue and market share, and to broaden patients'access to hepatitis C treatment. The list price could reduce out-of-pocket expenses for certain patients, such as thosecovered by the Medicare Part D drug benefit, versus competing drugs, Adam Schechter, Merck's head of human health, saidon a conference call.

Mr. Schechter didn't rule out providing discounts on Zepatier, saying Merck planned to "compete in all segments ofthe market and to have an appropriate discounting strategy that allows us to have access." He didn't specify themagnitude of any discounts. Bernstein analyst Tim Anderson said in a research note Wednesday he believes Merck isoffering a 15% discount off the list price to payers.

According to Merck spokeswoman Pam Eisele, "we expect [Zepatier's] price, as well as our comprehensive access strategy to seek broad coverage across commercial and public segments, will help broaden and accelerate patient access to treatment.”…….http://www.firstwordpharma.com/node/1354848?tsid=28&region_id=2#axzz3z8MOkyDk…...we expect the launch of Zepatier to further drive net price reductions for all market participants."

StephenW

默克Zepatier定价

http://www.nasdaq.com/article/me ... date-20160203-00914

默克设定一个标价为54,600 $病人Zepatier了12周的治疗，下面的列表价格与净值，价格打折后这些药物线的竞争，从基列和艾伯维公司的药物，虽然超过30％，根据默克。

默克公司表示，预计价格为Zepatier最大限度地发挥其收入和市场份额，并扩大患者对丙肝治疗的机会。标价可降低外的自付费用对某些患者，如那些由医疗保险D部分药物福利覆盖，与竞争药物，亚当·谢克特，人类健康的默克公司的负责人，在电话会议上说。

谢克特先生不排除提供有关Zepatier折扣，说默克计划“在所有的细分市场竞争，并有相应的折扣策略，可以让我们有机会。”他没有具体说明任何折扣的幅度。 Bernstein分析师蒂姆·安德森在一份研究报告周三表示，他认为，默克公司提供15％的折扣定价为纳税人。


据默克女发言人帕姆艾泽勒，“我们预计[Zepatier]的价格，以及我们寻求跨越商业和公共段覆盖面广，将有助于扩大和加速患者获得全面的访问策略treatment.”…….http://www.firstwordpharma.com/n ... _id=2#axzz3z8MOkyDk…...we预计推出Zepatier，进一步推动净降价为所有市场参与者“。

hengyin

Zepatier是什么东西？

StephenW

回复 hengyin 的帖子

ZEPATIER is a fixed-dose combination product containing elbasvir, a hepatitis C
virus (HCV) NS5A inhibitor,and grazoprevir, an HCV NS3/4A protease inhibitor,
and is indicated with or without ribavirin for treatment of chronic HCVgenotypes 1
or 4 infection in adults.
ZEPATIER是一个包含固定剂量组合产品elbasvir，丙型肝炎
病毒（HCV）NS5A抑制剂和grazoprevir，的HCV NS3 / 4A蛋白酶抑制剂
并表示有或没有利巴韦林治疗慢性HCV基因型1的
或4感染的成人。